Top

Published in:

01-12-2010 | Clinical Article

Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients

Authors: Constantin Roder, Vera Peters, Hidetoshi Kasuya, Tsutomu Nishizawa, Yayoi Takehara, Daniela Berg, Claudia Schulte, Nadia Khan, Marcos Tatagiba, Boris Krischek

Published in: Acta Neurochirurgica | Issue 12/2010

Abstract

Background

The etiology of Moyamoya disease (MMD) is still widely unknown. Several publications on Moyamoya describe differences of cytokine and growth factor concentrations in different specimen. We analyzed the DNA of patients with MMD for single nucleotide polymorphisms (SNPs) in and upstream of the genes for previously described associated cytokines and growth factors.

Method

Thirteen SNPs were genotyped in or upstream to four genes—basic fibroblast growth factor (BFGF), cellular retinoic acid-binding protein 1 (CRABP1), platelet derived growth factor receptor beta (PDGFRB), and transforming growth factor beta 1 (TGFB1)—comparing 40 DNA samples of MMD patients to 68 healthy controls from central Europe. Genotyping was performed by sequencing the SNP-containing genetic regions with custom made primers.

Findings

We found association of two SNPs: rs382861 [A/C] (p = 0.0373, OR = 1.81, 95% CI = 1.03–3.17) in the promoter region of PDGFRB and rs1800471[C/G] (p = 0.0345, OR = 7.65, 95% CI = 0.97–59.95), located in the first exon of TGFB1.

Conclusion

Our results indicate possible genetic risk factors for the genesis of MMD. TGFB1 and PDGFRB are involved in vascular growth and transformation processes which may play a role in the development of MMD. Further analyses in larger European cohorts and replication in patients of different ethnicity, as well as functional studies, may lead to possible early detection of patients at risk for developing MMD and subsequently to future preventive therapies.

Achrol AS, Guzman R, Lee M, Steinberg GK (2009) Pathophysiology and genetic factors in Moyamoya disease. Neurosurg Focus 26:E4CrossRefPubMed

Aoyagi M, Fukai N, Matsushima Y, Yamamoto M, Yamamoto K (1993) Kinetics of 125I-PDGF binding and down-regulation of PDGF receptor in arterial smooth muscle cells derived from patients with Moyamoya disease. J Cell Physiol 154:281–288CrossRefPubMed

Aoyagi M, Fukai N, Sakamoto H, Shinkai T, Matsushima Y, Yamamoto M, Yamamoto K (1991) Altered cellular responses to serum mitogens, including platelet-derived growth factor, in cultured smooth muscle cells derived from arteries of patients with moyamoya disease. J Cell Physiol 147:191–198CrossRefPubMed

Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, Kim DH, Pannu H, Willing MC, Sparks E, Pyeritz RE, Singh MN, Dalman RL, Grotta JC, Marian AJ, Boerwinkle EA, Frazier LQ, LeMaire SA, Coselli JS, Estrera AL, Safi HJ, Veeraraghavan S, Muzny DM, Wheeler DA, Willerson JT, Yu RK, Shete SS, Scherer SE, Raman CS, Buja LM, Milewicz DM (2009) Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 84:617–627CrossRefPubMed

Hojo M, Hoshimaru M, Miyamoto S, Taki W, Nagata I, Asahi M, Matsuura N, Ishizaki R, Kikuchi H, Hashimoto N (1998) Role of transforming growth factor-1 in the pathogenesis of Moyamoya disease. J Neurosurg 89:623–629CrossRefPubMed

Hoshimaru M, Takahashi JA, Kikuchi H, Nagata I, Hatanaka M (1991) Possible roles of basic fibroblast growth factor in the pathogenesis of Moyamoya disease: an immunohistochemical study. J Neurosurg 75:267–270CrossRefPubMed

Houkin K, Yoshimoto T, Abe H, Nagashima K, Nagashima M, Takeda M, Isu T (1998) Role of basic fibroblast growth factor in the pathogenesis of Moyamoya disease. Neurosurg Focus 5:4CrossRef

Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T (1999) Mapping of a familial moyamoya disease gene to chromosome 3p24.2–p26. Am J Hum Genet 64:533–537CrossRefPubMed

Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M (2000) Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 15:179–182CrossRefPubMed

10.

Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, Cho BK, Kim SK (2010) Plasma matrix metalloproteinases, cytokines, and angiogenic factors in Moyamoya disease. J Neurol Neurosurg Psychiatry 81(6):673–678CrossRefPubMed

11.

Kang HS, Kim SK, Cho BK, Kim YY, Hwang YS, Wang KC (2006) Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery 58:1074–1080CrossRefPubMed

12.

Kim SK, Yoo JI, Cho BK, Hong SJ, Kim YK, Moon JA, Kim JH, Chung YN, Wang KC (2003) Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke 34:2835–2841CrossRefPubMed

13.

Kuriyama S, Kusaka Y, Fujimura M, Wakai K, Tamakoshi A, Hashimoto S, Tsuji I, Inaba Y, Yoshimoto T (2008) Prevalence and clinicoepidemiological features of Moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke 39:42–47CrossRefPubMed

14.

Liu W, Hashikata H, Inoue K, Matsuura N, Mineharu Y, Kobayashi H, Kikuta K, Takagi Y, Hitomi T, Krischek B, Zou L, Fang F, Herzig R, Kim J, Kang H, Oh C, Tregouet D, Hashimoto N, Koizumi A (2009) A rare asian founder polymorphism of raptor may explain the high prevalence of moyamoya disease among east asians and its low prevalence among caucasians. Environ Health Prev Med 15:94–104CrossRef

15.

Malek AM, Connors S, Robertson RL, Folkman J, Scott RM (1997) Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in Moyamoya and central nervous system disorders. Pediatr Neurosurg 27:182–189CrossRefPubMed

16.

Miano JM, Berk BC (2000) Retinoids: versatile biological response modifiers of vascular smooth muscle phenotype. Circ Res 87:355PubMed

17.

Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, Ikeda H, Houkin K, Takagi Y, Kikuta K, Nozaki K, Hashimoto N, Koizumi A (2008) Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology 70:2357–2363CrossRefPubMed

18.

Mineharu Y, Takenaka K, Yamakawa H, Inoue K, Ikeda H, Kikuta KI, Takagi Y, Nozaki K, Hashimoto N, Koizumi A (2006) Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting. J Neurol Neurosurg Psychiatry 77:1025–1029CrossRefPubMed

19.

Mohren S, Weiskirchen R (2009) Non-synonymous gene polymorphisms in the secretory signal peptide of human TGF-[beta]1 affect cellular synthesis but not secretion of TGF-[beta]1. Biochem Biophys Res Commun 379:1015–1020CrossRefPubMed

20.

Nanba R, Tada M, Kuroda S, Houkin K, Iwasaki Y (2005) Sequence analysis and bioinformatics analysis of chromosome 17q25 in familial moyamoya disease. Childs Nerv Syst 21:62–68CrossRefPubMed

21.

Raines EW (2004) PDGF and cardiovascular disease. Cytokine Growth Factor Rev 15:237–254CrossRefPubMed

22.

Ross R (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801–809CrossRefPubMed

23.

Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, Arinami T (2004) A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 49:278–281CrossRefPubMed

24.

Scott RM, Smith ER (2009) Moyamoya disease and Moyamoya syndrome. N Engl J Med 360:1226–1237CrossRefPubMed

25.

Suzuki J, Takaku A (1969) Cerebrovascular" Moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288–299PubMed

26.

Takeuchi K, Shimizu K (1957) Hypoplasia of the bilateral internal carotid arteries. Brain Nerve 9:37–43

27.

Yamamoto M, Aoyagi M, Fukai N, Matsushima Y, Yamamoto K (1998) Differences in cellular responses to mitogens in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 29:1188–1193PubMed

28.

Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue T, Ikezaki K, Matsushima T, Fukui M (2000) Linkage of familial moyamoya disease (spontaneous occlusion of the circle of willis) to chromosome 17q25. Stroke 31:930–935PubMed

29.

Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG (1997) Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 99:S58–S60CrossRefPubMed

30.

Yoshimoto T, Houkin K, Takahashi A, Abe H (1996) Angiogenic factors in Moyamoya disease. Stroke 27:2160–2165PubMed

Title: Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients
Authors: Constantin Roder
Vera Peters
Hidetoshi Kasuya
Tsutomu Nishizawa
Yayoi Takehara
Daniela Berg
Claudia Schulte
Nadia Khan
Marcos Tatagiba
Boris Krischek
Publication date: 01-12-2010
Publisher: Springer Vienna
Published in: Acta Neurochirurgica / Issue 12/2010
Print ISSN: 0001-6268
Electronic ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-010-0711-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients

Abstract

Background

Method

Findings

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Method

Findings

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2010

Role of degenerated neuron density of dorsal root ganglion on anterior spinal artery vasospasm in subarachnoid hemorrhage: experimental study

Comparison of electrode location between immediate postoperative day and 6 months after bilateral subthalamic nucleus deep brain stimulation

The effect of lung-protective permissive hypercapnia in intracerebral pressure in patients with subarachnoid haemorrhage and ARDS. A retrospective study

Is MRI a reliable tool to locate the electrode after deep brain stimulation surgery? Comparison study of CT and MRI for the localization of electrodes after DBS

Pros and cons of permissive hypercapnia in patients with subarachnoid haemorrhage and ARDS

Can systematic analysis of morbidity and mortality reduce complication rates in neurosurgery?